Cd70 combination therapy
Assigneeargenx BVBA
InventorLuc VAN ROMPAEY
Life of this patent
Estimating the term…
Abstract
The present invention relates to combination therapies for the treatment of malignancy, particularly myeloid malignancy such as acute myeloid leukemia (AML). The combination therapies may include an antibody molecule that binds to CD70 and at least one antibody molecule that binds to a leukemic stem cell target. Preferred leukemic stem cell targets are TIM-3, IL1R3/IL1RAP and CD47.
Claims40
A combination comprising an antibody molecule that binds to CD70 and at least one antibody molecule that binds to a leukemic stem cell (LSC) target.
(canceled)
-10. (canceled)
(canceled)
-25. (canceled)
(canceled)
(canceled)
-43. (canceled)
-49. (canceled)
A combination comprising an antibody molecule that binds to CD70 and an agent that inhibits SIRPα signaling.
-62. (canceled)
-84. (canceled)
Dependencies are inferred from the claim text.